Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2012, Vol. 17 ›› Issue (12): 1413-1418.

Previous Articles     Next Articles

Reversal of the anticoagulant effect of dabigatran etexilate

TAN Sheng-lan1, ZHOU Xin-min2, PENG Juan1, ZHANG Wei1, LIU Zhao-qian1, ZHOU Hong-hao1, LI Zhi1   

  1. 1Institute of Clinical Pharmacology, Central South University, Changsha 410078,Hunan,Cnina;
    2Department of Cardio-thoracic Surgery, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan,China
  • Received:2012-08-17 Revised:2012-09-20 Published:2012-12-31

Abstract: Dabigatran etexilate is a new oral anticoagulant that acts as a direct thrombin inhibitor. Dabigatran etexilate generally shows good efficacy and safty, however, bleeding is the most common side effect which is slightly lower than or similar to that of warfarin or enoxaparin. In certain clinical situations including major bleeding and requirement of surgery or invasive procedure, clinicians will have to reverse the anticoagulant effect of dabigatran etexilate emergently. So far no antidote for dabigatran etexilate has been established.The management of bleeding resulting from dabigatran etexilate should be individualized based on the location and severity of the hemorrhage. Tests including thrombin clotting time (TT) and ecarin clotting time (ECT) will be helpful to determine the reversal of the anticoagulant effect of dabigatran etexilate.

Key words: Dabigatran etexilate, Reversal, Anticoagulant effect, Bleeding

CLC Number: